Table III.
Results of meta-analysis for methylenetetrahydrofolate reductase (MTHFR) gene Ala222Val and Glu429Ala polymorphism and bladder cancer risk.
| Genetic model | Recessive model | Dominant model | Homozygote | Heterozygote | |||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|||||
| Ala222Val | No. of study (sample size case/control) | Val/Val vs. Val/Ala + Ala/Ala | Val/Val + Val/Ala vs. Ala/Ala | Val/Val vs. Ala/Ala | Val/Ala vs. Ala/Ala | ||||
|
|
|
|
|
||||||
| OR (95% CI) | Ph | OR (95% CI) | Ph | OR (95% CI) | Ph | OR (95% CI) | Ph | ||
| Overall | 11 (3,463/3,927) | 1.00 (0.87–1.15) | 0.130 | 1.01 (0.87–1.17) | 0.024 | 1.02 (0.80–1.29) | 0.019 | 1.02 (0.92–1.12) | 0.103 |
| Ethnicity | |||||||||
| Chinese | 3 (701/875) | 1.32 (0.80–2.15) | 0.070 | 1.19 (0.79–1.78) | 0.029 | 1.42 (0.72–2.78) | 0.016 | 1.16 (0.93–1.45) | 0.146 |
| European | 3 (1,515/1,445) | 0.89 (0.72–1.11) | 0.747 | 0.90 (0.78–1.05) | 0.485 | 0.86 (0.68–1.09) | 0.629 | 0.92 (0.79–1.07) | 0.558 |
| American | 3 (904/1,100) | 0.93 (0.71–1.22) | 0.759 | 0.98 (0.71–1.36) | 0.063 | 0.95 (0.71–1.26) | 0.690 | 0.97 (0.66–1.43) | 0.031 |
| Middle East | 2 (343/507) | 0.87 (0.54–1.40) | 0.184 | 0.98 (0.74–1.30) | 0.270 | 0.87 (0.53–1.44) | 0.134 | 1.00 (0.75–1.34) | 0.440 |
| Source of control | |||||||||
| PB | 3 (641/843) | 0.83 (0.60–1.14) | 0.496 | 0.92 (0.74–1.13) | 0.109 | 0.78 (0.56–1.11) | 0.589 | 0.86 (0.57–1.29) | 0.057 |
| HB | 8 (2,822/3,084) | 1.08 (0.86–1.35) | 0.099 | 1.06 (0.89–1.25) | 0.033 | 1.12 (0.83–1.50) | 0.013 | 1.03 (0.92–1.15) | 0.203 |
|
| |||||||||
| Glu429Ala | No. of study (sample size case/control) | Ala/Ala vs. Ala/Glu + Glu/Glu | Ala/Ala + Ala/Glu vs. Glu/Glu | Ala/Ala vs. Glu/Glu | Ala/Glu vs. Glu/Glu | ||||
|
|
|
|
|
||||||
| OR (95% CI) | Ph | OR (95% CI) | Ph | OR (95% CI) | Ph | OR (95% CI) | Ph | ||
|
| |||||||||
| Overall | 9 (3,177/3,257) | 0.96 (0.79–1.15) | 0.182 | 1.15 (0.94–1.41) | <0.001 | 1.11 (0.78–1.58) | 0.009 | 1.16 (0.95–1.40) | 0.002 |
| Ethnicity | |||||||||
| Chinese | 2 (551/575) | 0.85 (0.35–2.07) | 0.891 | 0.97 (0.75–1.25) | 0.595 | 0.85 (0.35–2.07) | 0.857 | 0.98 (0.76–1.27) | 0.599 |
| European | 2 (1,379/1,078) | 0.86 (0.66–1.14) | 0.335 | 1.03 (0.89–1.20) | 0.515 | 0.88 (0.66–1.17) | 0.512 | 1.06 (0.91–1.24) | 0.333 |
| American | 3 (904/1,097) | 0.86 (0.62–1.18) | 0.801 | 0.98 (0.82–1.17) | 0.915 | 0.86 (0.62–1.20) | 0.781 | 1.01 (0.84–1.21) | 0.963 |
| Middle East | 2 (343/507) | 1.82 (1.11–3.01) | 0.129 | 2.16 (1.16–4.01) | 0.032 | 2.35 (0.75–7.40) | 0.040 | 2.11 (1.26–3.53) | 0.089 |
| Source of control | |||||||||
| PB | 3 (641/841) | 0.93 (0.64–1.36) | 0.839 | 1.13 (0.92–1.39) | 0.188 | 0.97 (0.66–1.44) | 0.726 | 1.16 (0.93–1.44) | 0.204 |
| HB | 6 (2,536/2,416) | 1.04 (0.72–1.51) | 0.052 | 1.15 (0.87–1.52) | <0.001 | 1.15 (0.68–1.93) | 0.001 | 1.14 (0.89–1.48) | 0.001 |
OR, odds ratio; CI, confidence interval; Ph, P-values for heterogeneity from Q test; PB, population-based; HB, hospital-based. Random-effects model was used when Ph<0.05; otherwise, fixed-model was used.